Next Article in Journal
Abundance of Plant-Associated Gammaproteobacteria Correlates with Immunostimulatory Activity of Angelica sinensis
Next Article in Special Issue
Reduction of Inflammation and Colon Injury by a Spearmint Phenolic Extract in Experimental Bowel Disease in Mice
Previous Article in Journal
Leri-Weill Dyschondrosteosis Syndrome: Analysis via 3DCT Scan
Open AccessReview

Zebrafish as an Emerging Model for Bioassay-Guided Natural Product Drug Discovery for Neurological Disorders

1
Molecular and Nanomedicine Research Unit (MNRU), Centre for Nanoscience and Nanotechnology (CNSNT), Sathyabama Institute of Science and Technology, Chennai 600119, Tamil Nadu, India
2
School of Health Sciences, Purdue University, West Lafayette, IN 47907, USA
*
Authors to whom correspondence should be addressed.
Medicines 2019, 6(2), 61; https://doi.org/10.3390/medicines6020061
Received: 29 April 2019 / Revised: 26 May 2019 / Accepted: 27 May 2019 / Published: 30 May 2019
  |  
PDF [2167 KB, uploaded 30 May 2019]
  |  

Abstract

Most neurodegenerative diseases are currently incurable, with large social and economic impacts. Recently, there has been renewed interest in investigating natural products in the modern drug discovery paradigm as novel, bioactive small molecules. Moreover, the discovery of potential therapies for neurological disorders is challenging and involves developing optimized animal models for drug screening. In contemporary biomedicine, the growing need to develop experimental models to obtain a detailed understanding of malady conditions and to portray pioneering treatments has resulted in the application of zebrafish to close the gap between in vitro and in vivo assays. Zebrafish in pharmacogenetics and neuropharmacology are rapidly becoming a widely used organism. Brain function, dysfunction, genetic, and pharmacological modulation considerations are enhanced by both larval and adult zebrafish. Bioassay-guided identification of natural products using zebrafish presents as an attractive strategy for generating new lead compounds. Here, we see evidence that the zebrafish’s central nervous system is suitable for modeling human neurological disease and we review and evaluate natural product research using zebrafish as a vertebrate model platform to systematically identify bioactive natural products. Finally, we review recently developed zebrafish models of neurological disorders that have the potential to be applied in this field of research. View Full-Text
Keywords: Alzheimer’s disease; bioassay-guided purification; drug discovery; natural products; neurodegenerative disorder; neurodegenerative model; Parkinson’s disease; schizophrenia; transgenic; zebrafish Alzheimer’s disease; bioassay-guided purification; drug discovery; natural products; neurodegenerative disorder; neurodegenerative model; Parkinson’s disease; schizophrenia; transgenic; zebrafish
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Pitchai, A.; Rajaretinam, R.K.; Freeman, J.L. Zebrafish as an Emerging Model for Bioassay-Guided Natural Product Drug Discovery for Neurological Disorders. Medicines 2019, 6, 61.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Medicines EISSN 2305-6320 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top